CRISPR Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 407
- Market Cap
- -
- Website
- http://www.crisprtx.com
- Introduction
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Clinical Trials
15
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
- Conditions
- Solid MalignancyHematologic Malignancy
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 70
- Registration Number
- NCT06208878
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Cedars Sinai, Los Angeles, California, United States
🇺🇸Stanford, Stanford, California, United States
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
- Conditions
- Pancreatic AdenocarcinomaEsophageal CarcinomaClear Cell Renal Cell CarcinomaCervical CarcinomaMalignant Pleural Mesothelioma
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 250
- Registration Number
- NCT05795595
- Locations
- 🇺🇸
Research Site 3, Duarte, California, United States
🇺🇸Research Site 7, Chicago, Illinois, United States
🇺🇸Research Site 6, Boston, Massachusetts, United States
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Conditions
- B-cell LymphomaLarge B-cell LymphomaB-cell MalignancyMantle Cell LymphomaMarginal Zone LymphomaNon-Hodgkin LymphomaChronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Follicular Lymphoma
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 120
- Registration Number
- NCT05643742
- Locations
- 🇦🇺
Research Site, Nedlands, Western Australia, Australia
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
- Conditions
- Diabetes MellitusMetabolic DiseaseImmune System DiseasesDiabetes Mellitus, Type 1Endocrine System DiseasesGlucose Metabolism DisordersAutoimmune Diseases
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 40
- Registration Number
- NCT05565248
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
- Conditions
- Metabolic DiseaseDiabetes Mellitus, Type 1Glucose Metabolism DisordersImmune System DiseasesAutoimmune DiseasesDiabetes MellitusEndocrine System Diseases
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 7
- Registration Number
- NCT05210530
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦LMC Manna, Toronto, Ontario, Canada
- Prev
- 1
- 2
- Next
News
T-Cell Lymphoma Pipeline Shows Promise with Novel Therapies and Regulatory Support
The T-Cell Lymphoma drug pipeline is advancing with key players like Eisai, Takeda, and Rhizen Pharmaceuticals developing innovative therapies.